Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Capital Employed (2016 - 2025)

Neurocrine Biosciences' Return on Capital Employed history spans 15 years, with the latest figure at 0.17% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 2.0% year-over-year to 0.17%; the TTM value through Dec 2025 reached 0.17%, down 2.0%, while the annual FY2025 figure was 0.18%, 1.0% down from the prior year.
  • Return on Capital Employed reached 0.17% in Q4 2025 per NBIX's latest filing, up from 0.16% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.19% in Q3 2024 to a low of 0.04% in Q2 2022.
  • Average Return on Capital Employed over 5 years is 0.12%, with a median of 0.11% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: decreased -24bps in 2021, then grew 11bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.06% in 2021, then soared by 154bps to 0.14% in 2022, then fell by -28bps to 0.1% in 2023, then skyrocketed by 75bps to 0.18% in 2024, then decreased by -9bps to 0.17% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Return on Capital Employed are 0.17% (Q4 2025), 0.16% (Q3 2025), and 0.15% (Q2 2025).